284 related articles for article (PubMed ID: 29466970)
1. A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Liu C; Li L; Lu WS; Du H; Yan LN; Wen TF; Wei WR; Jiang L; Xu MQ
BMC Cancer; 2018 Feb; 18(1):216. PubMed ID: 29466970
[TBL] [Abstract][Full Text] [Related]
2. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization.
Liu C; Li L; Lu WS; Du H; Yan LN; Yang JY; Wen TF; Zeng GJ; Jiang L; Yang J
Sci Rep; 2017 Oct; 7(1):13873. PubMed ID: 29066730
[TBL] [Abstract][Full Text] [Related]
4. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
5. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
7. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
[TBL] [Abstract][Full Text] [Related]
8. Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization.
Zhou D; Liang J; Xu LI; He F; Zhou Z; Zhang Y; Chen M
Oncol Lett; 2016 May; 11(5):2987-2994. PubMed ID: 27123051
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization.
Liu C; Jia BS; Zou BW; Du H; Yan LN; Yang JY; Jiang L; Wen TF; Lu WS
Medicine (Baltimore); 2017 Nov; 96(45):e8512. PubMed ID: 29137051
[TBL] [Abstract][Full Text] [Related]
10. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
Pinato DJ; Sharma R
Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
[TBL] [Abstract][Full Text] [Related]
11. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
12. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
13. [Clinical application value of prognosis of nutrition index and apparent diffusion coefficient in patient with hepatocellular carcinoma underwent transarterial chemoembolization].
Sun WH; Zhang AD; Li W
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(33):2581-2585. PubMed ID: 31510716
[No Abstract] [Full Text] [Related]
14. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.
Xu X; Chen W; Zhang L; Miao R; Zhou Y; Wan Y; Dong Y; Liu C
Chin Med J (Engl); 2014; 127(24):4204-9. PubMed ID: 25533822
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive nutritional index for predicting overall survival in hepatocellular carcinoma patients after multiple transarterial chemoembolization.
Deng J; He JJ; Xie LP; Zheng QW; Wu SL; Shao HY
Asia Pac J Clin Nutr; 2021; 30(1):7-14. PubMed ID: 33787035
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]